Kura Oncology, Inc.
Kura Oncology, Inc. (KURA): 12 pipeline candidates · 6 upcoming catalysts · ~20 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
19.8 months
D/E 5.05 · 0% dilution
Lead: Approved
12 candidates
6 upcoming, next in ~1962d
0 buys · 20 sells (180d)
A transparent, data-derived signal for Kura Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$818.1M
Cash
$39.1M
Quarterly Burn
$85.9M
Runway
19.8 mo
Revenue
$18.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| cabozantinib | Phase 1 |
| darlifarnib | Phase 1 |
| fludarabine | Phase 1 |
| gilteritinib | Phase 1 |
| granulocyte colony-stimulating factor | Phase 1 |
| idarubicin | Phase 3 |
| imatinib | Phase 1 |
| ko-2806 | Phase 1 |
| ko-7246 | Preclinical |
| komzifti | Approved |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
218
Total value held
$718.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,637,531 | $78.4M |
| suvretta capital management, llc | 8,575,422 | $69.7M |
| bvf inc/il | 8,445,769 | $68.7M |
| vanguard capital management llc | 7,571,370 | $61.6M |
| state street corp | 4,511,891 | $36.7M |
| armistice capital, llc | 3,736,000 | $30.4M |
| prosight management, lp | 3,356,700 | $27.3M |
| deep track capital, lp | 2,643,542 | $21.5M |
| aqr capital management llc | 2,124,480 | $17.3M |
| geode capital management, llc | 2,034,276 | $16.5M |
Showing top 10 of 218 institutional holders of Kura Oncology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kura Oncology, Inc.'s pipeline?
Kura Oncology, Inc. (KURA) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kura Oncology, Inc.'s lead drug candidate?
Kura Oncology, Inc.'s most advanced tracked candidate is cabozantinib (Phase 1) for Solid Tumors With HRAS Alterations.
What is Kura Oncology, Inc.'s next catalyst?
Kura Oncology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit" — expected November 1, 2031.
What is Kura Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kura Oncology, Inc. has approximately 19.8 months of cash runway.
What is Kura Oncology, Inc.'s market capitalization?
Kura Oncology, Inc.'s market capitalization is approximately $818.1M.
Get the full picture on Kura Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.